NR4A1 and breast cancer: In this trial, the carboplatin-VELI arm enrolled 72 patients with HER2-negative BC, including both hormone receptor-positive (HR+) and hormone receptor negative (HR−, i.e., triple-negative BC, TNBC), who received oral VELI 50 mg twice a day (BID) during 12 weeks and 4 cycles of 3-weekly carboplatin AUC 6 during the paclitaxel sequence (VELI-CARBO) [19] (Figure 1).